Corona Remedies delivered a solid Q2 FY26 with revenue of ₹361 crore (+15% YoY), EBITDA of ₹78.5 crore (+17.4% YoY), and PAT of ₹52 crore (+22% YoY).
Financial stats pending filing verification
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
The new hormonal plant's commercial production and WHO/EU GMP approvals are expected only by FY27-end; any delay could push international revenue contribution further out.
medium · management_commentaryPCPM for reps with 0-3 years experience is only ₹2-2.5 lakh vs. ₹8 lakh for tenured reps; rapid MR addition (5-7% annually) could pressure overall productivity.
medium · analyst_questionManagement plans to enter infertility, spine, CNS, etc., but has not provided specific timelines or investment details beyond infertility; competitive intensity may limit success.
medium · data_observation